John Bryant - Concepedia

Author

John Bryant

Also Known As

A Branch, Bryant John, Bryant, John, Bryant, John L., Bryant,J. L., Calif Speck Raleigh, J Bryant, J L Bryant, J. Bryant, J. L. BRYANT

384

Publications

41.2K

Citations

H-Index

268

Concepts

All Affiliations

University of Pittsburgh NSABP Foundation UPMC Hillman Cancer Center University of Birmingham Northwestern University

About

John Bryant is an author at University of Pittsburgh specializing in medicine, oncology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	11	14	336
2	Arts	8	8	250
3	Education	4	4	47
4	Health Sciences	4	4	339
5	Business	3	3	188

John Bryant

115

Publications

37K

Citations

H-Index

Page 1

	Year	Citations
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer Soonmyung Paik, Steven Shak, Gong Tang, New England Journal of Medicine	2004	6.3K
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer Bernard Fisher, Stewart Anderson, John Bryant, New England Journal of Medicine	2002	6.1K
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond, Edith A. Perez, John Bryant, New England Journal of Medicine	2005	5.3K
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer Soonmyung Paik, Gong Tang, Steven Shak, Journal of Clinical Oncology	2006	2.6K
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Bernard Fisher, John Bryant, Norman Wolmark, Journal of Clinical Oncology	1998	2.2K
Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation Bernard Fisher, Jong‐Hyeon Jeong, Stewart Anderson, New England Journal of Medicine	2002	1.4K
Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I William P. Hausdorff, John Bryant, Peter R. Paradiso, Clinical Infectious Diseases VaccinationVaccine SafetyConjugate FormulationConjugate Vaccine FormulationsVaccine Development	2000	870
Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors Bernard Fisher, James J. Dignam, John Bryant, JNCI Journal of the National Cancer Institute	1996	868
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond, Journal of Clinical Oncology	2005	801
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28 Eleftherios P. Mamounas, John Bryant, Barry C. Lembersky, Journal of Clinical Oncology	2005	710

Page 1